OBJECTIVE: To systematically evaluate the effectiveness and economics of trimebutine maleate combined with bifidobacterium triple viable bacteria in the treatment of irritable bowel syndrome（ IBS）. METHODS:CNKI

Wanfang database

VIP database

CBM

Pub Med

EMBase and the Cochrane Library were retrieved until Mar. 2020. Meta-analysis was performed on randomized controlled trials of efficacy of trimebutine maleate combined with bifidobacterium triple viable bacteria（ study group） versus trimebobutin maleate alone（ control group） in the treatment of IBS. From the perspective of medical care system

the cost-effectiveness analysis method was used to evaluate the economics of the two treatment regimens. The sensitivity analysis was carried out by cost decrease of 10%and treatment efficiency fluctuation of 10%. RESULTS: Totally 11 literature were collected

including 1 312 patients.Meta-analysis showed that the total clinical effective rate of the study group was significantly better than that of the control group

and the difference was statistically significant（ RR = 1. 24

95% CI = 1. 18-1. 30

P < 0. 000 01）. No severe adverse drug reactions were found in both groups. The economic evaluation results indicated that the costeffectiveness ratio of the study group regimen was 256. 52 and its incremental cost-effectiveness ratio was 793. 33 compared with the control group

that is

the control group scheme was better when the patient’s willingness to pay was ≤793. 33 yuan

when the patient’s willingness to pay was > 793. 33 yuan

the study group scheme was better.The results of sensitivity analysis showed that the results of economic evaluation were relatively robust.CONCLUSIONS: The clinical efficacy of trimebutine maleate combined with bifidobacterium triple viable bacteria in the treatment of IBS is better than that of trimebutine maleate alone

clinicians can choose whether to use combined regimen according to patients’ willingness to pay.